Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.



UK Activity at CPhI Worldwide

With the appointment of the new Prime Minister came the creation of a few new government departments. Please note, therefore, that UKTI has now transitioned across to the Department for International Trade and you will see some changes in email signatures, branding etc being rolled out.

Read the rest of entry »

Lilly and AstraZeneca Receive FDA Fast Track Designation for AZD3293, an Investigational Treatment for Early Alzheimer's Disease

22 August 2016: Windlesham, UK & Indianapolis, USA - Eli Lilly and Company and AstraZeneca today announced they have received U.S. Food and Drug Administration (FDA) Fast Track designation for the development program in Alzheimer's disease for AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in phase 3 clinical trials. The FDA's Fast Track program is designed to expedite the development and review of new therapies to treat serious conditions and tackle key unmet medical needs.

Read the rest of entry »

Thermo Fisher Scientific Launches Science World in France

22 August 2016: Loughborough, UK - Thermo Fisher Scientific, the world leader in serving science, announces it will bring Fisher Scientific “Science World” to the Palais de la Musique et des Congrès in Strasbourg on 29 September 2016.

Read the rest of entry »

Edinburgh Science-park Earmarked for Expansion

22 August 2016: Edinburgh, UK - Expansion plans are being drawn up to secure future growth at the Edinburgh BioQuarter science park. Funding for projects there has also been earmarked from the City Deal.Senior figures from Scottish Enterprise (SE) said in May that they were working to accommodate the “growing pipeline” of inquiries from firms looking to establish operations at the site, which is located at Little France.

Read the rest of entry »

Cambridge Innovation Capital Raises £75 million Via Private Financing

19 August 2016: Cambridge, UK - Cambridge Innovation Capital plc, a preferred investor for the University of Cambridge and a Cambridge-based investor in technology and healthcare companies, announces that it has raised £75m of new capital (the “Fundraising”).

Read the rest of entry »

PCI Pharma Services Welcomes Jim Neville As Operations Director at its Tredegar, UK site

15 August 2016: Philadelphia, USA & Tredegar, UK - Leading pharmaceutical outsourcing services provider PCI Pharma Services has announced the appointment of Jim Neville as Operations Director at its Tredegar, UK site, to lead the continuing growth of its manufacturing business.

Read the rest of entry »

KalVista Announces Initiation of a Phase 1 Clinical Trial of KVD818 for the Treatment of Hereditary Angioedema

11 August 2016: Salisbury, UK & Cambridge USA – KalVista Pharmaceuticals today announced the dosing of the first subject in a first-in-human clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally delivered KVD818 in healthy volunteers.  A KalVista discovery, KVD818 is a novel, potent, and selective inhibitor of plasma kallikrein in development for the prevention of attacks of edema in patients with hereditary angioedema (HAE).

Read the rest of entry »

SynbiCITE and Rainbow Seed Fund Announce New £200k Competition for Engineering Biology

11 August 2016: London, UK - Bio-start, an annual competition designed to bolster UK companies aiming to solve significant global problems through synthetic biology has been launched.

Read the rest of entry »

PCI to Host Free Webinar on the Development and Manufacturing of Highly Potent Molecules

11 August 2016: Philadelphia, USA –  The successful development and manufacturing of highly potent molecules is the theme of the next free, specialist webinar from leading pharmaceutical outsourcing provider PCI Pharma Services (Thursday, September 8, 10am EDT / 3pm GMT).

Read the rest of entry »

Summit Reports Positive Phase 1 Data and Outlines Route to Market Strategy for DMD Candidate Ezutromid

Oxford, UK,  - Summit Therapeutics plc, the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD') and Clostridium difficile infection, today reports Phase 1 clinical trial results that show a new formulation of ezutromid (referred to as 'F6') achieved a greater than six-fold increase in maximum plasma levels in DMD patients compared to those achieved with the current clinical formulation (referred to as 'F3') with only two fifths of the dose.

Read the rest of entry »

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.

OBN Noticeboard

This is an impromptu noticeboard to let people know about events, other things that are happening, perhaps lab equipment for sale etc.  Just drop an email to us, team@obn.org.uk, and we will post.